Tevogen Names Leadership Team to Execute Diversified Growth Strategy

Rhea-AI Summary

Tevogen (Nasdaq: TVGN) named interim leaders across five core verticals to execute an initial diversified growth strategy and announced potential acquisitions expected to operate as subsidiaries.

The company said the targeted transactions could collectively generate annual revenues exceeding $50 million and are expected to close by Q2 2026, subject to customary due diligence and definitive agreements.

Positive

• Potential revenue >$50M from targeted subsidiaries
• Targeted transaction timeline: expected close by Q2 2026
• Interim leadership assigned across five verticals to execute strategy

Negative

• Planned transactions are subject to due diligence and definitive agreements, creating completion uncertainty
• Revenue figure is projected and not guaranteed despite the >$50M estimate

WARREN, N.J., March 09, 2026 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN) today announced the appointment of interim leaders across its core business verticals to execute the first phase of its diversified growth strategy.

In this first phase, Tevogen is evaluating strategic opportunities that, if completed, are expected to operate as subsidiaries of the Company and could collectively generate annual revenues exceeding $50 million. The Company expects these transactions to close by the second quarter of 2026, subject to customary due diligence and definitive agreements.

Leadership Designations:

• Digital Health: Arpita Patel and Wojtek Stobinski
• Generics: Sadiq Khan and David Banko
• Contract Research: William Keane
• Biotech: Lori Grosso
• Artificial Intelligence: Mittul Mehta
  

About Tevogen

Tevogen is a socially integrated healthcare enterprise built on the principles of affordability, efficiency, and scientific rigor. The company leverages artificial intelligence and precision T cell therapy platforms, a patient-first and cost-disciplined operating model, and engagements with global technology leaders to support the development of advanced, life-saving therapies across multiple therapeutic areas and scalable solutions for the broader healthcare system.

Tevogen Bio, the company’s lead initiative, has completed a proof-of-concept clinical trial demonstrating the potential of its single-HLA-restricted, genetically unmodified allogeneic T cells. Tevogen Bio’s pipeline spans virology, oncology, and neurology, with programs built on the company’s proprietary ExacTcell™ platform.

Tevogen.AI is designed to transform drug development by accelerating target detection, helping reduce failure rates, and supporting optimized clinical trial design through proprietary predictive technologies. The platform utilizes cloud and data services from leading technology providers, including Microsoft and Databricks, to advance its long-term ambition to predict the proteome for any given protein–HLA combination, enabling rapid and cost-efficient therapeutic discovery.

Tevogen is exploring future strategic initiatives that may include domestic generics, biosimilars, medical devices, and innovative insurance solutions for healthcare providers. Together, these programs reflect Tevogen’s mission to advance sustainable innovation and broaden patient access through a faster, more efficient, and more equitable healthcare model.

Forward Looking Statements

This press release contains certain forward-looking statements, including without limitation statements relating to: the potential transactions and the potential benefits of the transactions; Tevogen’s plans for its research and manufacturing capabilities; expectations regarding future growth; expectations regarding the healthcare and biopharmaceutical industries; and Tevogen’s development of, the potential benefits of, and patient access to its product candidates for the treatment of infectious diseases and cancer. Forward-looking statements can sometimes be identified by words such as “may,” “could,” “would,” “expect,” “anticipate,” “possible,” “potential,” “goal,” “opportunity,” “project,” “believe,” “future,” and similar words and expressions or their opposites. These statements are based on management’s expectations, assumptions, estimates, projections and beliefs as of the date of this press release and are subject to a number of factors that involve known and unknown risks, delays, uncertainties and other factors not under the company’s control that may cause actual results, performance or achievements of the company to be materially different from the results, performance or other expectations expressed or implied by these forward-looking statements.

Factors that could cause actual results, performance, or achievements to differ from those expressed or implied by forward-looking statements include, but are not limited to: risks inherent in diligence and negotiation of the proposed transactions; the risk that the transactions may not be consummated on favorable terms or at all; the risk that the expected benefits of the transactions may not be realized on a timely basis or at all; changes in the markets in which Tevogen competes, including with respect to its competitive landscape, technology evolution, or regulatory changes; changes in domestic and global general economic conditions; the risk that Tevogen may not be able to execute its growth strategies or may experience difficulties in managing its growth and expanding operations; the risk that Tevogen may not be able to develop and maintain effective internal controls; the failure to achieve Tevogen’s commercialization and development plans and identify and realize additional opportunities, which may be affected by, among other things, competition, the ability of Tevogen to grow and manage growth economically and hire and retain key employees; the risk that Tevogen may fail to keep pace with rapid technological developments to provide new and innovative products and services or make substantial investments in unsuccessful new products and services; that Tevogen will need to raise additional capital to fully realize its business plans; risks related to the ability to develop, license or acquire new therapeutics; the risk of regulatory lawsuits or proceedings relating to Tevogen’s business; uncertainties inherent in the execution, cost, and completion of preclinical studies and clinical trials; risks related to regulatory review, approval and commercial development; risks associated with intellectual property protection; Tevogen’s limited operating history; and those factors discussed or incorporated by reference in Tevogen’s most recent Annual Report on Form 10-K and subsequent filings with the SEC.

You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. Tevogen undertakes no obligation to update any forward-looking statements, except as required by applicable law.

Contacts

Tevogen Bio Communications
T: 1 877 TEVOGEN, Ext 701
Communications@Tevogen.com

FAQ

What did Tevogen (TVGN) announce on March 9, 2026 about its growth strategy?

Tevogen announced interim leaders across five verticals and a plan to pursue strategic transactions. According to the company, the first-phase deals could operate as subsidiaries and collectively target more than $50 million in annual revenue, with closings expected by Q2 2026.

Which leaders did Tevogen (TVGN) appoint to execute the diversified strategy?

Tevogen named interim leaders for Digital Health, Generics, Contract Research, Biotech, and AI verticals. According to the company, named executives include Arpita Patel, Wojtek Stobinski, Sadiq Khan, David Banko, William Keane, Lori Grosso, and Mittul Mehta.

How much revenue could Tevogen's (TVGN) targeted transactions generate and when?

The targeted transactions could collectively generate annual revenues exceeding $50 million. According to the company, those deals are expected to close by Q2 2026, subject to customary due diligence and definitive agreements.

What are the main risks Tevogen (TVGN) disclosed about the planned transactions?

The company said the transactions remain subject to customary due diligence and definitive agreements, creating timing and completion risk. According to the company, expected closings by Q2 2026 depend on successful negotiation and regulatory or contractual approvals.